Skip to content

A study on the clinical efficacy of Ginseng-Astragalus Delayed Failure Formula in treating frailty in the elderly

A study on the clinical efficacy of Ginseng-Astragalus Delayed Failure Formula in treating frailty syndrome in the elderly

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000197
Enrollment
Unknown
Registered
2024-08-09
Start date
2024-08-18
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Frailty

Interventions

1:Oral formula for 3 months, in the form of soup, 1 dose per day, Take half a dose in the morning and half a dose in the evening, before meals or half an

Sponsors

Xiyuan Hospital of China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 85 Years

Inclusion criteria

Inclusion criteria: (1) Meets the diagnostic criteria for Fried frailty. (2) Comply with the diagnostic criteria of spleen qi deficiency in traditional Chinese medicine. (3) Age 60-85 years old, gender is not limited. (4) Volunteer subjects signed an informed consent form. (5) The frailty patients are combined with chronic diseases, such as hypertension, diabetes mellitus, coronary heart disease, etc., and are treated with routine medication. Physical examination and auxiliary examination show that the control is effective, can be included. (6) Patients with malignant tumours who have been evaluated as CR (complete remission) after treatment and whose treatment has ended 3 years after enrolment.

Exclusion criteria

Exclusion criteria: (1) Patients who cannot co-operate with the assessment due to cognitive impairment, limitation of voluntary activities, etc; (2) Patients with cardiovascular, cerebrovascular, digestive, respiratory, haematological, neurological and endocrine metabolic diseases who have been hospitalised twice in the past year. (2) Patients with cardiovascular, cerebrovascular, digestive, respiratory, haematological, neurological and endocrine metabolic diseases who have been hospitalised twice in the past 1 year and whose conditions are often unstable; (3) Patients with malignant tumour, whose evaluation is not CR, and who are clinically recommended for surgical/non-surgical treatment; (4) Patients with liver and renal insufficiency, abnormal transaminases and creatinine; (5) In addition to the above diseases, due to the combination of other diseases currently treatment can not be interrupted, or the need for repeated hospitalisation can not cooperate with the Regular treatment; (6) Patients participating in other clinical trials; (7) Patients who are allergic to the drugs in this formula; (8) Patients who are using hormone therapy for other diseases.

Design outcomes

Primary

MeasureTime frame
Chinese Medicine Evidence Rating Scale;Frailty Phenotype;short physical performance battery,SPPB;

Countries

China

Contacts

Public ContactZhou Qingbing

Xiyuan Hospital of China Academy of Chinese Medical Sciences

zhouqingbing0910@163.com+86 137 1678 4090

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026